Primary central nervous system lymphomas: A validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4245-4253

  Braggio, Esteban ^a   McPhail, Ellen Remstein ^b   Macon, William ^b   Lopes, M Beatriz ^c   Schiff, David ^c   Law, Mark ^b   Fink, Stephanie ^b   Sprau, Debra ^b   Giannini, Caterina ^b   Dogan, Ahmet ^b   Fonseca, Rafael ^a   O'Neill, Brian Patrick ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME; CHROMOSOME 3Q; CHROMOSOME 8Q; CHROMOSOME DELETION; CHROMOSOME DELETION 6P21; CHROMOSOME DELETION 6Q; CHROMOSOME DELETION 9P21; CHROMOSOME GAIN 12Q12; CHROMOSOME GAIN 12Q24; CHROMOSOME IDENTIFICATION; CHROMOSOME PAIRING; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KARYOTYPE; MALE; ONCOGENE; ONCOGENE ETV6; ONCOGENE FOXP1; ONCOGENE NCOA2; ONCOGENE TEL; ONCOGENE TMEM30A; ONCOGENE TOX; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; VALIDATION PROCESS;

AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; FIXATIVES; FORMALDEHYDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PARAFFIN EMBEDDING;

EID: 79960297332     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0395     Document Type: Article

References (34)

1. Ferreri AJ, Reni M. Primary central nervous system lymphoma. Crit Rev Oncol Hematol 2007;63:257-68. (Pubitemid 47126863)
2. Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504-10.
3. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711-5. (Pubitemid 46631313)
4. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281-8. (Pubitemid 46622031)
5. Panageas KS, Elkin EB, DeAngelis LM, Ben-Porat L, Abrey LE. Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer 2005;104:2466-72.
6. Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864-71. (Pubitemid 28108718)
7. O'Neill BP. Neurocognitive outcomes in primary CNS lymphoma (PCNSL). Neurology 2004;62:532-3. (Pubitemid 38252790)
8. Louis DN, Posner J, Jacobs T, Kaplan R. Report of the Brain Tumor Progress Review Group. NCI-NINDS PRG report. NIH: Bethesda, MD; 2000. NIH Publication No. 01-4902.
9. Flordal Thelander E, Ichimura K, Collins VP, Walsh SH, Barbany G, Hagberg A, et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 2007;31:1219-30.
10. Taborelli M, Tibiletti MG, Martin V, Pozzi B, Bertoni F, Capella C. Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genet Cytogenet 2006;165:106-13. (Pubitemid 43343503)
11. Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 2008;26: 4814-9.
12. Rinaldi A, Kwee I, Poretti G, Mensah A, Pruneri G, Capello D, et al. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. Br J Haematol 2006;134:27-36. (Pubitemid 43830024)
13. Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch Neurol 2010;67:291-7.
14. O'Neill BP, Kelly PJ, Earle JD, Scheithauer B, Banks PM. Computer-assisted stereotaxic biopsy for the diagnosis of primary central nervous system lymphoma. Neurology 1987;37:1160-4. (Pubitemid 17123448)
15. Paris PL, Sridharan S, Scheffer A, Tsalenko A, Bruhn L, Collins C. High resolution oligonucleotide CGH using DNA from archived prostate tissue. Prostate 2007;67:1447-55. (Pubitemid 47435791)
16. Hostetter G, Kim SY, Savage S, Gooden GC, Barrett M, Zhang J, et al. Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples. Nucleic Acids Res 2010;38:e9.
17. Johnson NA, Hamoudi RA, Ichimura K, Liu L, Pearson DM, Collins VP, et al. Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest 2006;86:968-78.
18. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large Bcell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82. (Pubitemid 38029949)
19. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res 2009;69:3579-88.
20. Lipson D, Aumann Y, Ben-Dor A, Linial N, Yakhini Z. Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol 2006;13:215-28.
21. Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de Jong D, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008;216:209-17.
22. Schwindt H, Vater I, Kreuz M, Montesinos-Rongen M, Brunn A, Richter J, et al. Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia 2009;23:1875-84.
23. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006;203:311-7. (Pubitemid 43290840)
24. Nakamura M, Kishi M, Sakaki T, Hashimoto H, Nakase H, Shimada K, et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 2003;63:737-41. (Pubitemid 36231967)
25. Thelander EF, Ichimura K, Corcoran M, Barbany G, Nordgren A, Heyman M, et al. Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia. Leuk Lymphoma 2008;49:477-87. (Pubitemid 351298331)
26. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008;105: 13520-5.
27. Sung CO, Kim SC, Karnan S, Karube K, Shin HJ, Nam DH, et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood 2011;117:1291-300.
28. Richter J, Ammerpohl O, Martin-Subero JI, Montesinos-Rongen M, Bibikova M, Wickham-Garcia E, et al. Array-based DNA methylation profiling of primary lymphomas of the central nervous system. BMC Cancer 2009;9:455.
29. Zhang XM, Chang Q, Zeng L, Gu J, Brown S, Basch RS. TBLR1 regulates the expression of nuclear hormone receptor co-repressors. BMC Cell Biol 2006;7:31.
30. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758-64. (Pubitemid 46582031)
31. Parker H, An Q, Barber K, Case M, Davies T, Konn Z, et al. The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes Chromosomes Cancer 2008;47:1118-25.
32. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004;116:511-26. (Pubitemid 38264429)
33. Li J, Wang CY. TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. Nat Cell Biol 2008;10:160-9. (Pubitemid 351194045)
34. Aliahmad P, Kaye J. Development of all CD4 T lineages requires nuclear factor TOX. J Exp Med 2008;205:245-56. (Pubitemid 351185730)